 So in principle, I think if we ignore the problem of blinding, which I'll get to in a moment, the MAP study, the two studies, MAP1 and MAP2, were designed in a way, interestingly, you have an idea, you think that MDMA combined with psychotherapy helps people more than nothing combined with psychotherapy, which is state-of-the-art, right? At least for many mood and anxiety disorders. And so what you do is you do therapy plus MDMA, then you do therapy plus placebo.